Urolog. pro Praxi, 2009; 10(1): 22-24

Phytotherapeutic in a treatment of benign prostatic hyperplasia

MUDr. Jaroslav Porš
Urologická ambulance Městské nemocnice Turnov

Phytotherapeutic agents present a large group of drugs that have been used for many years in a treatment of benign prostatic hyperplasia.

These agents are composed of various healing components that have not very well known and still quite unclear mechanism of

action. Among the main advantages of plant extracts belong the lack of side effects. The authors of this article present short overview

on actual phytotherapy, including basic information about plants that are mainly used for extraction of these drugs.

Keywords: benign prostatic hyperplasia, phytotherapeutic agents, plant extracts.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Porš J. Phytotherapeutic in a treatment of benign prostatic hyperplasia. Urol. praxi. 2009;10(1):22-24.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Šafařík L, Povýšil C. Benigní hyperplazie prostaty. In: Dvořáček J, et al: Urologie, Praha, ISV, 1998.
    2. Dreikorn K, Borkowski A, Braeckman J, et al. Other medical therapies. In: Denis L, Griffiths K, Khoury S et al (eds). Proceedings of the 4th International Consultation on BPH, 1997. Plymouth United Kingdom, Health Publications, 1998: 633-659.
    3. Herbert L, Franklin CL. Evoluation and nonsurgical management of benign prostatic hyperplasia. In: Campbell´s Urology CRRom, Walsh PC, Retik AB, Vaughan ED, Wein AJ, Volume 2, Section 6, Chapter 39, Copyright 2003, Elsevier Science (USA).
    4. Kliment J. Medikamentózna liečba benígnej hyperplázie prostaty. In: Kliment J, Horňák M. Benígna hyperplázia prostaty. Martin: Osveta 1996.
    5. DiSilverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37: 77-83. Go to original source...
    6. Weisser H, Tunn S, Behnke B, et al. Effects of the Sabal serrulata extract IDS89 and its subtractions on 5-alpha reductase activity in human benign prostatic hyperplasia. Prostate 1996; 28: 300-306. Go to original source...
    7. Kolombo I. Lekce EUNI - Benigní hyperplazie prostaty, 2006 (www.euni.cz).
    8. Veselský Z, Macek P, Novák J. Farmakoterapie benigní hyperplazie prostaty, Supplementum B, Urolog. pro Praxi 5/2006.
    9. Levin RM, Riffaud JP, Bellamy F et al. Effects of Tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 1996; 156: 2084-2088. Go to original source... Go to PubMed...
    10. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 1998; 280: 1604-1609. Go to original source... Go to PubMed...
    11. Berges RR, Windeler J, Tampisch H, et al. Randomized, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995; 345: 1529-1532. Go to original source... Go to PubMed...
    12. Berges RR, Kassen A, Senget T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18-month follow-up. Br J Urol 2000; 85: 842-846. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.